Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases

Publisher： Bentham Science Publishers

E-ISSN： 2212-2710|7|3|259-267

ISSN： 1872-213X

Source： Recent Patents on Inflammation & Allergy Drug Discovery, Vol.7, Iss.3, 2013-09, pp. : 259-267

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

KIR Molecules: Recent Patents of Interest for the Diagnosis and Treatment of Several Autoimmune Diseases, Chronic Inflammation, and B-cell Malignancies

By  

Recent Patents on DNA & Gene Sequences, Vol. 5, Iss. 3, 2011-01 ,pp. : 169-174

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Patents on Immunoregulatory DNA Vaccines for Autoimmune Diseases and Allograft Rejection

By  

Recent Patents on DNA & Gene Sequences, Vol. 4, Iss. 2, 2010-06 ,pp. : 122-131

Bentham Science Publishers

Access to resources Recommend Favorite

APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 5, Iss. 3, 2011-09 ,pp. : 184-199

Bentham Science Publishers

Access to resources Recommend Favorite

Current Concepts in the Diagnosis and Treatment of Type 1 and Type 2 Autoimmune Pancreatitis

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 5, Iss. 2, 2011-05 ,pp. : 136-149

Bentham Science Publishers

Access to resources Recommend Favorite

Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 3, Iss. 3, 2009-11 ,pp. : 177-187

Bentham Science Publishers

Access to resources Recommend Favorite